Rapamune的效果好吗？

The discovery and research of drugs are always accompanied by the process of human beings fighting against various diseases of their own. Among them, some drugs have been gradually replaced in the long history, while others continue to bring people new surprises as people understand them. For example, aspirin has been "unlocked" with new skills in recent years, and the cardiovascular disease drug propranolol (propranolol) has become the absolute mainstay in the treatment of infantile hemangiomas. Leipanming () is such a drug that is being fully understood by people and has developed new treatment indications. It can be described as a "cross-border" new star.   

Rapamune, formerly known as Rapamycin Rapamune (RPM), is a lipophilic triene nitrogen-containing macrolide antibiotic compound produced by Streptomyces hygroscopieus isolated from soil samples of Easier Island in the Pacific by Vezina and others at Ayerst Laboratory in Canada in 1975. It was initially used as a low-toxic antifungal drug. In 1977, it was found to have immunosuppressive effects. In 1989, RAPA began to be tried out as a new drug to treat rejection of organ transplants. Judging from the effects of animal experiments and clinical applications, it is a new immunosuppressant with good efficacy, low toxicity, and no nephrotoxicity. Compared with cyclosporine, Rapamune oral solution has a smaller dose (only 2 to 3 mg per dose), stronger anti-rejection effect, and fewer side effects. Therefore, since its launch, Rapamune has quickly become a commonly used oral immunosuppressant for organ transplant recipients around the world (especially kidney transplants). Rapamune is a serine/threonine kinase regulated by phosphoinositide-3-kinase and an mTOR (mammalian target of rapamycin) inhibitor. mTOR is a protein that controls many cellular processes, including angiogenesis and cell synthesis, making it a reasonable target for inhibiting severe vascular tumors. Recently, in a number of clinical research reports involving vascular malformations and refractory vascular tumors, rapamycin () has been proven to have a significant effect in vascular and lymphoproliferative diseases.